Pharsight

Saphris generic

Saphris is an atypical antipsychotic drug owned by Allergan. The active ingredient in Saphris is asenapine maleate. The drug was first authorized for market use on 13th August, 2009.

When will Saphris generic be available?

The generic versions of Saphris are expected to be released after the expiry of the last Saphris patent on 6th October, 2026. This date stipulates when it's legally permissible for other manufacturers to produce a generic Saphris.

Saphris uses

Saphris is primarily used for the treatment of schizophrenia in adults, bipolar disorder, and manic or mixed episodes associated with bipolar I disorder. Its active ingredient, asenapine maleate, plays an integral role in these treatments. It's especially effective as an adjunctive treatment to lithium or valproate in adults and for acute monotherapy of manic or mixed episodes in pediatric patients aged 10 to 17.

Saphris patent expiration

Saphris is protected by a total of 4 patents, none of which have expired. The last Saphris patent will expire on 6th October, 2026, paving the way for generic Saphris. Below are the details of the patent:

Saphris dosage

Want to ask something?